Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.

BMC health services research - 5 Mar 2022

Boyer Sylvie, Baudoin Maël, Nishimwe Marie Libérée, Santos Melina, Lemoine Maud, Maradan Gwenaëlle, Sylla Babacar, Kouanfack Charles, Carrieri Patrizia, Mourad Abbas, Rouveau Nicolas, Moh Raoul, Seydi Moussa, Attia Alain, Woode Maame Esi, Lacombe Karine

Abstract excerpt

BACKGROUND: Although direct-acting antivirals (DAA) have become standard care for patients with chronic hepatitis C worldwide, there is no evidence for their value for money in sub-Saharan Africa. We assessed the cost-effectiveness of four sofosbuvir-based regimens recommended by the World Health Organization (WHO) in Cameroon, Côte d'Ivoire and Senegal. METHODS: Using modelling, we simulated chronic hepatitis C...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Sofosbuvir

Share to World Health Organization

Source

Open in PubMed Open full text

Identifiers

PMID: 35248039
DOI: 10.1186/s12913-021-07289-0
PMCID: PMC8897946

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa.PMID 35248039Read ↗

Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.Semantic proximity Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK.Semantic proximity Read ↗

Opportunities for cost reduction of current first-line WHO-recommended oral antiretroviral therapy: replacing tenofovir disoproxil fumarate with tenofovir alafenamideSemantic proximity Read ↗

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.Semantic proximity Read ↗

Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.Semantic proximity Read ↗

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.Semantic proximity Read ↗

Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.Semantic proximity Read ↗

Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.Semantic proximity Read ↗

Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).Semantic proximity Read ↗

Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.Semantic proximity Read ↗

Economic evaluation of pan-genotypic generic direct-acting antiviral regimens for treatment of chronic hepatitis C in Iran: a cost-effectiveness study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.